UPB Stock Analysis: Buy, Sell, or Hold?
UPB - Upstream Bio, Inc. Common Stock
$6.42
0.11 (1.74%)
▲
5d:
+0.31%
30d:
-14.51%
90d:
-31.7%
HOLD
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
TODAY
Get Alerted When UPB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: UPB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: UPB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: UPB is currently trading at $6.42, which is considered oversold relative to its 30-day fair value range of $6.50 to $7.49.
Technical Outlook: Technically, UPB is in a strong downtrend. Immediate support is located at $6.09, while resistance sits at $7.08.
Market Sentiment: UPB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Implied Volatility is high (75th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $38.25 (+495.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, UPB is in a strong downtrend. Immediate support is located at $6.09, while resistance sits at $7.08.
Market Sentiment: UPB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Implied Volatility is high (75th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $38.25 (+495.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.50 -
$7.49
Company Quality Score
47/100
(HOLD)
Options IV Signal
75th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
45.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 75th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 495.8% below Wall St target ($38.25)
Trading Range Analysis
30-Day Trading Range
$6.50 -
$7.49
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.61
(25.1%)
Support & Resistance Levels
Support Level
$6.09
Resistance Level
$7.08
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.22
Wall Street Target
$38.25
(+495.8%)
Revenue Growth (YoY)
82.7%
Share & Embed Analysis
Last updated: August 04, 2026 2:07 AM ET
Data refreshes hourly during market hours. Next update: 3:07 AM
Data refreshes hourly during market hours. Next update: 3:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UPB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Gray
SELL
852 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 54 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 59 HOLD |
